Corrigendum to: Decrease in clinical hypoglycemia in young children with type 1 diabetes treated with free-mixed aspart and detemir insulin: an open labeled randomized trial (Pediatric Diabetes, (2015), 16, (345-353), 10.1111/pedi.12156);Decrease in clinical hypoglycemia in young children with type 1 diabetes treated with free-mixed aspart and detemir insulin: An open labeled randomized trial

Pediatric Diabetes

Volumn 16, Issue 5, 2015, Pages 345-353

  Petit Bibal, C ^a   Rothenbuhler, A ^a   Lucchini, P ^a   Aboumrad, B ^a   Castell, A L ^a   Le Fur, S ^a   Bougneres P ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Aspart detemir mixture; Diabetes children; Hypoglycemia; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; INSULIN LISPRO; ISOPHANE INSULIN; ANTIDIABETIC AGENT; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ACYLATION; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 1; DRUG COMBINATION; METABOLISM; PRESCHOOL CHILD;

ADOLESCENT; BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DRUG COMBINATIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN, ISOPHANE; MALE;

EID: 84936200371     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12511     Document Type: Erratum

References (35)

1. Miles HL, Acerini CL. Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus. Paediatr Drugs 2008: 10: 163-176.
2. Mohn A, Dunger DB, Chiarelli F. The potential role of insulin analogues in the treatment of children and adolescents with type 1 diabetes mellitus. Diabetes Nutr Metab 2001: 14: 349-357.
3. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001: 24: 296-301.
4. Braun D, Konrad D, Lang-Muritano M, Schoenle E. Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes. Pediatr Diabetes 2008: 9 (4 Pt 2): 382-387.
5. Roberts A, Standl E, Bayer T, Munksgaard EC, Lang H. Efficacy and safety of 6-month treatment with insulin detemir in type 1 diabetic patients on a basal-bolus regimen. Diabetologia 2001: 44 (Suppl. 1): A207.
6. Vague P, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003: 26: 590-596.
7. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet Med 2007: 24: 27-34.
8. de Beaufort CE, Lange K, Swift PG et al. Metabolic outcomes in young children with type 1 diabetes differ between treatment centers: the Hvidoere Study in Young Children 2009. Pediatr Diabetes 2013: 14: 422-428.
9. de Beaufort CE, Swift PG, Skinner CT et al. Continuing stability of center differences in pediatric diabetes care: do advances in diabetes treatment improve outcome? The Hvidoere Study Group on Childhood Diabetes. Diabetes Care 2007: 30: 2245-2250.
10. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997: 277: 925-926.
11. (ICH) ICoH. Topic E6: Harmonised tripartite guidelines for good clinical practice, step 5. Consolidated Guideline 1596 Federal Register. 1997: 62: 25691-25709.
12. Silverstein J, Klingensmith G, Copeland K et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005: 28: 186-212.
13. NICE. Type 1 Diabetes: Diagnosis and Management of Type 1 Diabetes in Children, Young People and Adults. Clinical guideline 15. London: NICE, 2004 (available from http://publications.nice.org.uk/type-1-diabetes-cg15).
14. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001: 358: 739-746.
15. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002: 4: 673-682.
16. Kordonouri O, Lauterborn R, Deiss D. Lipohypertrophy in young patients with type 1 diabetes. Diabetes Care 2002: 25: 634.
17. Cody D. Infant and toddler diabetes. Arch Dis Child 2007: 92: 716-719.
18. Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet 1999: 354: 1604-1607.
19. Danne T, Datz N, Endahl L et al. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr Diabetes 2008: 9: 554-560.
20. Danne T, Lupke K, Walte K, Von Schuetz W, Gall MA. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003: 26: 3087-3092.
21. Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004: 53: 1614-1620.
22. Roach P. New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations. Clin Pharmacokinet 2008: 47: 595-610.
23. Cryer PE, Gerich JE. Hypoglycemia in insulin dependent diabetes mellitus: insulin excess and defective glucose counterregulation. In: Rifkin H, Porte D, eds. Diabetes Mellitus: Theory and Practice. 4th edn. New York: Elsevier, 1990: 526-546.
24. Davis EA, Keating B, Byrne GC, Russell M, Jones TW. Hypoglycemia: incidence and clinical predictors in a large population-based sample of children and adolescents with IDDM. Diabetes Care 1997: 20: 22-25.
25. Kapellen TM, Heidtmann B, Bachmann J, Ziegler R, Grabert M, Holl RW. Indications for insulin pump therapy in different age groups: an analysis of 1, 567 children and adolescents. Diabet Med 2007: 24: 836-842.
26. Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002: 141: 490-495.
27. Sulli N, Shashaj B. Long-term benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes: a 4-year follow-up. Diabet Med 2006: 23: 900-906.
28. Weintrob N, Benzaquen H, Galatzer A et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics 2003: 112: 559-564.
29. Willi SM, Planton J, Egede L, Schwarz S. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr 2003: 143: 796-801.
30. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 1999: 16: 332-338.
31. Kurtzhals P. Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int J Obes Relat Metab Disord 2004: 28 (Suppl. 2): S23-S28.
32. White NH, Cleary PA, Dahms W et al. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001: 139: 804-812.
33. Fiallo-Scharer R, Horner B, McFann K, Walravens P, Chase HP. Mixing rapid-acting insulin analogues with insulin glargine in children with type 1 diabetes mellitus. J Pediatr 2006: 148: 481-484.
34. Cengiz E, Swan KL, Tamborlane WV, Sherr JL, Martin M, Weinzimer SA. The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin. Diabetes Care 2012: 35: 690-692.
35. Nguyen TM, Renukuntla VS, Heptulla RA. Mixing insulin aspart with detemir does not affect glucose excursion in children with type 1 diabetes. Diabetes Care 2010: 33: 1750-1752.